Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

Не применимо Завершено NCT03472664

Кратко

The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults with mild cognitive impairment. The data collected will help determine whether diet interventions induce changes in cognitive function, cerebral blood flow, and levels of certain proteins and hormones in body fluids. The study will include volunteers who have mild cognitive impairment, who will be randomly assigned to receive either a ketogenic low-carbohydrate diet or a low-fat diet for 16-weeks, with follow-up assessment 8 weeks after diet completion. Study measures, clinic visits and phone sessions will occur at baseline and throughout the 24-week study. Participant will follow either a low-carbohydrate or low-fat diet that will be individually planned with help from a study dietitian. After completing the study diet for 16 weeks, participants will resume their normal diet. The final visits will occur at week 24 (8 weeks after the completing the diet). At the end of the 24-week study, participants will be given the opportunity to meet with the study dietitian for education and assistance with planning

Cerebrospinal Fluid Abeta42

baseline · pg/ml

Cerebrospinal Fluid Abeta42

week 16 · pg/ml

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss — Eli Lilly and Company
• Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia — Icahn School of Medicine at Mount Sinai
• Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges — Brigham and Women's Hospital
• Technology and Family Thriving Study — University of California, Santa Barbara
• Community-based Brain Health Program to Address Dementia Risk — Posit Science Corporation
• Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzhei — Georgetown University

Все исследования